Study to compare the effect of casirivimab and imdevimab, remdesivir, and favipiravir on progression and multi-organ function of hospitalized COVID-19 patients
Coronavirus disease 2019 (COVID-19) caused a progress in research to find a solution to this pandemic. Also, various advances in pharmacotherapy against COVID-19 have emerged. Regarding antiviral therapy, casirivimab and imdevimab are antibodies combination against COVID-19. Standard antiviral thera...
| Main Authors: | , , |
|---|---|
| 格式: | Article |
| 語言: | English |
| 出版: |
De Gruyter
2023-08-01
|
| 叢編: | Open Medicine |
| 主題: | |
| 在線閱讀: | https://doi.org/10.1515/med-2023-0768 |
| _version_ | 1827596129304313856 |
|---|---|
| author | Hegazy Sahar K. Tharwat Samar Hassan Ahmed H. |
| author_facet | Hegazy Sahar K. Tharwat Samar Hassan Ahmed H. |
| author_sort | Hegazy Sahar K. |
| collection | DOAJ |
| description | Coronavirus disease 2019 (COVID-19) caused a progress in research to find a solution to this pandemic. Also, various advances in pharmacotherapy against COVID-19 have emerged. Regarding antiviral therapy, casirivimab and imdevimab are antibodies combination against COVID-19. Standard antiviral therapy against COVID-19 includes remdesivir and favipiravir. The objectives were to compare progression and multi-organ function of hospitalized COVID-19 patients between these three antiviral groups. 265 COVID-19 hospitalized patients were included in this study and were divided into 3 groups (1:2:2), respectively, Group (A): casirivimab and imdevimab, group (B): remdesivir, and group (C): favipiravir. The design of the study is a single blind non-randomized controlled trial. This study is a phase IV clinical trial (post-marketing study). The duration of the study was about 6 months after receiving the ethical approval. Casirivimab and imdevimab achieved less case progression as presented by lower World Health Organization scale (P < 0.05 in comparing group A with B and C) and better multi-organ functions as presented by lower Sequential Organ Function Assessment score (P < 0.05 in comparing group A with B and C) than remdesivir and favipiravir. From all these results, it is concluded that Group A (casirivimab and imdevimab) produces better outcomes than B (remdesivir) and C (favipiravir) intervention groups. |
| first_indexed | 2024-03-09T03:06:08Z |
| format | Article |
| id | doaj.art-91cb15e0f39e4fd3b3a6b01f032f2fe1 |
| institution | Directory Open Access Journal |
| issn | 2391-5463 |
| language | English |
| last_indexed | 2024-03-09T03:06:08Z |
| publishDate | 2023-08-01 |
| publisher | De Gruyter |
| record_format | Article |
| series | Open Medicine |
| spelling | doaj.art-91cb15e0f39e4fd3b3a6b01f032f2fe12023-12-04T08:00:00ZengDe GruyterOpen Medicine2391-54632023-08-01181716910.1515/med-2023-0768Study to compare the effect of casirivimab and imdevimab, remdesivir, and favipiravir on progression and multi-organ function of hospitalized COVID-19 patientsHegazy Sahar K.0Tharwat Samar1Hassan Ahmed H.2Clinical Pharmacy Department, Faculty of Pharmacy, Tanta University, Tanta, PC: 31511, EgyptRheumatology and Immunology Department, Faculty of Medicine, Mansoura University, Mansoura, PC: 35511, EgyptClinical pharmacy Department, Mansoura University Hospital, Mansoura, PC: 35511, EgyptCoronavirus disease 2019 (COVID-19) caused a progress in research to find a solution to this pandemic. Also, various advances in pharmacotherapy against COVID-19 have emerged. Regarding antiviral therapy, casirivimab and imdevimab are antibodies combination against COVID-19. Standard antiviral therapy against COVID-19 includes remdesivir and favipiravir. The objectives were to compare progression and multi-organ function of hospitalized COVID-19 patients between these three antiviral groups. 265 COVID-19 hospitalized patients were included in this study and were divided into 3 groups (1:2:2), respectively, Group (A): casirivimab and imdevimab, group (B): remdesivir, and group (C): favipiravir. The design of the study is a single blind non-randomized controlled trial. This study is a phase IV clinical trial (post-marketing study). The duration of the study was about 6 months after receiving the ethical approval. Casirivimab and imdevimab achieved less case progression as presented by lower World Health Organization scale (P < 0.05 in comparing group A with B and C) and better multi-organ functions as presented by lower Sequential Organ Function Assessment score (P < 0.05 in comparing group A with B and C) than remdesivir and favipiravir. From all these results, it is concluded that Group A (casirivimab and imdevimab) produces better outcomes than B (remdesivir) and C (favipiravir) intervention groups.https://doi.org/10.1515/med-2023-0768antiviralscasirivimab and imdevimabcovid-19favipiravirremdesivir |
| spellingShingle | Hegazy Sahar K. Tharwat Samar Hassan Ahmed H. Study to compare the effect of casirivimab and imdevimab, remdesivir, and favipiravir on progression and multi-organ function of hospitalized COVID-19 patients Open Medicine antivirals casirivimab and imdevimab covid-19 favipiravir remdesivir |
| title | Study to compare the effect of casirivimab and imdevimab, remdesivir, and favipiravir on progression and multi-organ function of hospitalized COVID-19 patients |
| title_full | Study to compare the effect of casirivimab and imdevimab, remdesivir, and favipiravir on progression and multi-organ function of hospitalized COVID-19 patients |
| title_fullStr | Study to compare the effect of casirivimab and imdevimab, remdesivir, and favipiravir on progression and multi-organ function of hospitalized COVID-19 patients |
| title_full_unstemmed | Study to compare the effect of casirivimab and imdevimab, remdesivir, and favipiravir on progression and multi-organ function of hospitalized COVID-19 patients |
| title_short | Study to compare the effect of casirivimab and imdevimab, remdesivir, and favipiravir on progression and multi-organ function of hospitalized COVID-19 patients |
| title_sort | study to compare the effect of casirivimab and imdevimab remdesivir and favipiravir on progression and multi organ function of hospitalized covid 19 patients |
| topic | antivirals casirivimab and imdevimab covid-19 favipiravir remdesivir |
| url | https://doi.org/10.1515/med-2023-0768 |
| work_keys_str_mv | AT hegazysahark studytocomparetheeffectofcasirivimabandimdevimabremdesivirandfavipiravironprogressionandmultiorganfunctionofhospitalizedcovid19patients AT tharwatsamar studytocomparetheeffectofcasirivimabandimdevimabremdesivirandfavipiravironprogressionandmultiorganfunctionofhospitalizedcovid19patients AT hassanahmedh studytocomparetheeffectofcasirivimabandimdevimabremdesivirandfavipiravironprogressionandmultiorganfunctionofhospitalizedcovid19patients |